Teva Pharmaceutical Industries Ltd (TEVA): Operating Cash Flow
$1.65B
Year ended 2025-12-31
$1.90B
Trailing 12 months to 2026-06-30
+1.2%
3-year compound annual growth
+6.3%
5-year compound annual growth
-11.4%
10-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.65B | +32.2% | 2026-02-03, From 2025-01-01 |
| 2024-12-31 | $1.25B | -8.8% | 2026-02-03, From 2024-01-01 |
| 2023-12-31 | $1.37B | -14.0% | 2026-02-03, From 2023-01-01 |
| 2022-12-31 | $1.59B | +99.2% | 2025-02-05, From 2022-01-01 |
| 2021-12-31 | $798.00M | -34.4% | 2024-02-12, From 2021-01-01 |
| 2020-12-31 | $1.22B | +62.6% | 2023-02-10, From 2020-01-01 |
| 2019-12-31 | $748.00M | -69.4% | 2022-02-09, From 2019-01-01 |
| 2018-12-31 | $2.45B | +9.9% | 2021-02-10, From 2018-01-01 |
| 2017-12-31 | $2.23B | -42.8% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $3.89B | -29.8% | 2019-02-19, From 2016-01-07 |
| 2015-12-31 | $5.54B | +8.1% | 2018-02-12, From 2015-01-01 |
| 2014-12-31 | $5.13B | +58.4% | 2017-02-15, From 2014-01-01 |
| 2013-12-31 | $3.24B | -29.2% | 2016-02-11, From 2013-01-01 |
| 2012-12-31 | $4.57B | +10.6% | 2015-02-09, From 2012-01-01 |
| 2011-12-31 | $4.13B | 0.0% | 2014-02-10, From 2011-01-01 |
| 2010-12-31 | $4.14B | +22.6% | 2013-02-12, From 2010-01-01 |
| 2009-12-31 | $3.37B | +4.4% | 2012-02-17, From 2009-01-01 |
| 2008-12-31 | $3.23B | +78.2% | 2011-02-15, From 2008-01-01 |
| 2007-12-31 | $1.81B | n/a | 2010-02-22, From 2007-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.65B | +32.2% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.98B | +12.6% |
| Viatris Inc (VTRS) | 2025-12-31 | $2.32B | +0.6% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $3.63B | n/m |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $1.40B | -12.3% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $2.90B | -1.7% |
| Abbott Laboratories (ABT) | 2025-12-31 | $9.57B | +11.8% |
| Organon & Co. (OGN) | 2025-12-31 | $700.00M | -25.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $14.16B | -6.8% |
Compare TEVA, REGN, VTRS, VRTX side by side · Screen every company in Pharmaceutical Preparations ↗